PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
Innhold levert av ReachMD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ReachMD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!
Gå frakoblet med Player FM -appen!
Combination Therapy for CLL: What Evidence Do We Have?
MP3•Episoder hjem
Manage episode 435106879 series 3128163
Innhold levert av ReachMD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ReachMD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
CME credits: 1.25
Valid until: 16-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/combination-therapy-for-cll-what-evidence-do-we-have/26497/
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
…
continue reading
Valid until: 16-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/combination-therapy-for-cll-what-evidence-do-we-have/26497/
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
528 episoder
MP3•Episoder hjem
Manage episode 435106879 series 3128163
Innhold levert av ReachMD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ReachMD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
CME credits: 1.25
Valid until: 16-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/combination-therapy-for-cll-what-evidence-do-we-have/26497/
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
…
continue reading
Valid until: 16-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/combination-therapy-for-cll-what-evidence-do-we-have/26497/
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
528 episoder
Alle episoder
×Velkommen til Player FM!
Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.